A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD
NCT00215436 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 345
Last updated 2010-11-10
Summary
The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.
Conditions
Interventions
- DRUG
-
Formoterol Fumarate
Sponsors & Collaborators
-
Dey
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-03-31
- Primary Completion
- 2005-09-30
- Completion
- 2006-09-30
Countries
- United States
Study Locations
More Related Trials
-
Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD
NCT00064402 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control
NCT01043601 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)
NCT01488019 ·Status: COMPLETED ·Phase: PHASE4
-
To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD
NCT00064415 ·Status: COMPLETED ·Phase: PHASE3
-
A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00685841 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol
NCT01023516 ·Status: COMPLETED ·Phase: PHASE2
-
A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease
NCT00403286 ·Status: COMPLETED ·Phase: PHASE2
-
Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)
NCT00742248 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo
NCT01072149 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary Disease
NCT01113593 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU
NCT00628862 ·Status: COMPLETED ·Phase: PHASE3
-
NVA237 Versus Placebo 12-week Efficacy Study
NCT01709864 ·Status: COMPLETED ·Phase: PHASE3
-
Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol
NCT01555099 ·Status: COMPLETED ·Phase: PHASE2
-
An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
NCT02294734 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)
NCT00383435 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT01437540 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
NCT00250679 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease
NCT00774761 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01054885 ·Status: COMPLETED ·Phase: PHASE3
-
Study in Subjects Greater Than 40 Years of Age With COPD
NCT00507234 ·Status: COMPLETED ·Phase: PHASE3
-
A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01053988 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01009463 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)
NCT00383721 ·Status: COMPLETED ·Phase: PHASE3
-
A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00691405 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD
NCT01946620 ·Status: COMPLETED ·Phase: PHASE3